Immunovia is more than one test – it is a platform and an approach.
IMMray™ PanCan-d is our first product, but battling pancreatic cancer is only the beginning for us at Immunovia. We believe that our blood contains enough information to detect any disease, even at early stages. And we believe we have the technology to do it.
Immunovia’s unique test platform and approach is based on a vast library of antibodies and very advanced bioinformatics, including machine learning algorithms helping us single out relevant biomarkers that together form a unique disease fingerprint. Our pipeline contains tests for several other cancers and autoimmune diseases.